Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3498 Challenges in the inclusion of patients with neuroendocrine and endocrine neoplasms in clinical trials (CTs): How to minimize screening failures (SF)

Introduction: Study coordinators working in a Clinical Trials Unit (CTU) are essential for the optimal development of CTs in oncology. Patients with neuroendocrine neoplasms (NENs) treated in CTs have specific challenges related to the heterogeneity of the disease, making their inclusion and screening process more complex.

Conference:

Presenting Author:

Authors: Perera J, Caparrós J, Hernando J, Garcia A, Esteban-Villarrubia J,

Keywords: Clinical trials unit, neuroendocrine neoplasm, Study coordinators, Screening failure, endocrine tumor, VHIO, Oncology, NET,

#3236 The role of clinical trials study coordinator (SC) in the era of theragnosis in neuroendocrine tumors (NETs): Challenges and opportunities

Introduction: Since new radiopharmaceuticals have emerged as cancer treatment, Lutecium177 in NET, and Radium-223 in prostate cancer, there has been an increase in clinical trials (CT) based on theragnosis. This scenario represents an organizational challenge to the coordination of nuclear medicine (NM), radiopharmacy (RP), and medical oncology (MO).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Perera J, Fernández I, Hernando J, Pérez C, Serra J,

Keywords: radiopharmaceuticals, NET, neuroendocrine tumor, theragnosis, radiopharmacy, medical oncology, nuclear medicine, Lutecium177, Radium-223, study coordinator, screening period, challenges and opportunities,